Anti-KOR-SA3544 (Human) mAb (Monoclonal Antibody)
Monoclonal antibody of 100 μg targeting KOR-SA3544 for FCM, WB.
| Target | KOR-SA3544 |
|---|---|
| Product Type | Antibody |
| Application | FCM, WB |
| Clonality | Monoclonal |
| Conjugate | Unlabeled |
| Isotype | IgG |
| Immunogen | KOCL-22 myeloid cell line derived from congenital leukemia |
| Host Species | Mouse |
| Species Reactivity | Human |
| Formulation | This antibody is lyophilized form. Prepare a stock solution by dissolving the lyophilized antibody in 100 mL of distilled water. After reconstitution, the IgG concentration will be 1 mg/mL in PBS (pH 7.2)/ 1% sucrose, 0.09% NaN3. |
| Research Area | Cell Biology |
| Description/Background | This monoclonal antibody (clone KOR-SA3544) was reactive with a surface antigen expressed on Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) without exception (26/26 cases). The recognized antigen is a nonspecific cross-reacting antigen (NCA)-50/90 (CD66c), one of the carcinoembryonic antigen (CEA)-related glycoproteins encoded by a member of the CEA gene family. The Philadelphia chromosome (Ph1) has been implicated as the causative factor in greater than 90% of chronic myelogenous leukemia (CML), in 25–30% of adult and 2–10% of childhood acute lymphoblastic leukemia (ALL) and in rare cases of acute myelogenous leukemia (AML). The presence of the Ph in leukemic cells of ALL patients usually indicates poor prognosis and high risk. Sequential monitoring of the Ph in ALL correlates with the activity of malignant clones and predicts impending clinical relapse, and therefore is useful in guiding clinical therapeutic decisions. |
| Storage Temperature | -20°C. Please refer to datasheet for additional information |
| Protocols | FCM, WB |
| Clone Number | KOR-SA3544 |
| Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |
Related Content
